Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib versus imatinib in newly diagnosed Ph+ ALL
NCT03589326Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Oct 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of ponatinib in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Takeda. Started Oct 2018; status: active, not recruiting.
02
Drugs
ponatinib
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT03589326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589326.